Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CanSino Biologics, Inc. Class H ( (HK:6185) ) has shared an announcement.
CanSino Biologics Inc. reported unaudited results for the first quarter ended March 31, 2026, showing operating revenue of RMB 190.3 million, up 38.7% year-on-year, but a widened net loss attributable to shareholders of RMB 40.4 million. The company also recorded significantly larger negative operating cash flow and higher basic and diluted loss per share, underscoring ongoing profitability and cash generation pressures despite revenue growth, and advised investors and shareholders to exercise caution when dealing in its shares.
The board, senior management and key financial officers jointly affirmed the accuracy and completeness of the quarterly figures, while noting that the report has not been audited by the company’s external auditor. Governance details, including the composition of the board and confirmation that the Chinese version of the report prevails in case of discrepancies, emphasize regulatory compliance and transparency as the group navigates its current loss-making phase.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$64.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a China-based biopharmaceutical company focused on the research, development and commercialization of vaccines. Listed in Hong Kong, the group targets domestic and international markets with innovative immunization products, positioning itself within the highly competitive global vaccine industry.
Average Trading Volume: 717,075
Technical Sentiment Signal: Sell
Current Market Cap: HK$12.95B
Learn more about 6185 stock on TipRanks’ Stock Analysis page.